Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05646888

Inflammation, Platelets and Sickle Cell Disease

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
25 (estimated)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Sickle cell disease (SCD) is an autosomal recessive genetic disorder linked to a single mutation on beta-globin chains. This leads to red blood cell deformation and chronic hemolysis which can result in vaso-occlusive events, anemia and vasculopathy. Pathophysiology is incompletely understood, and beyond red blood cell's abnormalities this involves hemostasis and innate immunity. The aim of our study is to describe the mechanisms of thrombo-inflammation during the vaso-occlusive crisis (VOC) in adults with sickle cell disease.

Detailed description

Pathophysiology of sickle cell disease is incompletely understood. The typical change of red blood cells into sickle cells lead to post-capillary stream abnormalities. This phenomenon is responsible of ischemia-reperfusion injuries. Chronic hemolysis is the second part of the pathophysiology. The consequences are vasoconstriction, endothelial lesions, chronic inflammation, hemostasis and platelets activation. Thrombo-inflammation concept was proposed by Tanguay to describe the interactions between hemostasis, platelets and innate immune cells (neutrophils polynuclear) during thrombotic process. Since this time, this concept was largely described in many clinical situations such as septicemia, COVID-19, coronaropathy, auto-immune diseases and sickle cell disease. In this project, we will study platelets activation and thrombo-inflammation markers in the beginning of a vaso-occlusive crisis, during the crisis and two months after the crisis. Blood samples will be collected during a routine care sample. Biological markers studied will be: * Soluble and surface markers of platelet activation; platelet-leukocytes aggregates * Plasmatic eicosanoids produced by platelets (TXB2) and immune cells * In vitro platelets reactivity; dynamic thrombus formation in normal and pathologic arterial blood stream * Platelet's inflammasome

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlood samplingthe blood sample will be taken during a planned blood sampling

Timeline

Start date
2023-01-15
Primary completion
2026-11-30
Completion
2026-11-30
First posted
2022-12-12
Last updated
2026-03-19

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05646888. Inclusion in this directory is not an endorsement.